The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer

Histopathology

Volumn 65, Issue 3, 2014, Pages 340-352

  Boyle, David P ^a   Mcart, Darragh G ^a   Irwin, Gareth ^a   Wilhelm Benartzi, Charlotte S ^b   Lioe, Tong F ^c   Sebastian, Elena ^a   Mcquaid, Stephen ^a   Hamilton, Peter W ^a   James, Jacqueline A ^a   Mullan, Paul B ^a   Catherwood, Mark A ^c   Harkin, D Paul ^a   Salto Tellez, Manuel ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Immunohistochemistry; Mutation; P53 protein; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PROTEIN P53; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TP53 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY COMBINING SITE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MIDDLE AGED; MISSENSE MUTATION; NONSENSE MUTATION; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TISSUE MICROARRAY; UNITED KINGDOM; BREAST TUMOR; COHORT ANALYSIS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84927570231     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12398     Document Type: Article

References (36)

1. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358; 15-16.
2. Vogelstein B, Sur S, Prives C. p53: the most frequently altered gene in human cancers. Nat. Educ. 2010; 3; 6.
3. Walerych D, Napoli M, Collavin L et al. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012; 33; 2007-2017.
4. Forbes SA, Bindal N, Bamford S et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2010; 39; 10-15.
5. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007; 25; 5287-5312.
6. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 2005; 97; 1180-1184.
7. Zhang D, Salto-Tellez M, Putti TC et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod. Pathol. 2003; 16; 79-84.
8. Ellis I, Pinder S, Bobrow L. Pathology reporting of breast disease: NHSBSP publication no. 58. 2005. Available at: http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp58.html (accessed 2 January 2012).
9. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010; 28; 2784-2795.
10. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
11. Walker RA, Bartlett JM, Dowsett M et al. HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 2008; 61; 818-824.
12. Bartlett JM, Starczynski J, Atkey N et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J. Clin. Pathol. 2011; 64; 649-653.
13. Kastelein F, Biermann K, Steyerberg EW et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013; 62; 1676-1683.
14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
15. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer 1989; 63; 181-187.
16. International Agency on Research for Cancer (IARC). IARC TP53 database.
17. Gonzalez D, Martinez P, Wade R et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J. Clin. Oncol. 2011; 29; 2223-2229.
18. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2012.
19. Venables WN, Ripley BD. Modern applied statistics with S. New York: Springer, 2002.
20. Therneau TM, Grambsch PM. Modelling survival data: extending the Cox model. New York: Springer, 2000.
21. Olivier M, Langerod A, Carrieri P et al. The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clin. Cancer Res. 2006; 12; 1157-1167.
22. Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res. 2012; 14; R70.
23. Abdel-Fatah TM, Powe DG, Agboola J et al. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J. Pathol. 2010; 220; 419-434.
24. Friedrichs K, Gluba S, Eidtmann H et al. Overexpression of p53 and prognosis in breast cancer. Cancer 1993; 72; 3641-3647.
25. Alsner J, Jensen V, Kyndi M et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol. 2008; 47; 600-607.
26. Sjogren S, Inganas M, Norberg T et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl Cancer Inst. 1996; 88; 173-182.
27. Yemelyanova A, Vang R, Kshirsagar M et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod. Pathol. 2011; 24; 1248-1253.
28. Ahrendt SA, Hu Y, Buta M et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J. Natl Cancer Inst. 2003; 95; 961-970.
29. Miyaki M, Iijima T, Yasuno M et al. High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas. Oncogene 2002; 21; 6689-6693.
30. Miller LD, Smeds J, George J et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. USA 2005; 102; 13550-13555.
31. Kandioler-Eckersberger D, Ludwig C, Rudas M et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 2000; 6; 50-56.
32. Andersson J, Larsson L, Klaar S et al. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann. Oncol. 2005; 16; 743-748.
33. Bonnefoi H, Piccart M, Bogaerts J et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol. 2011; 12; 527-539.
34. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486; 395-399.
35. Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472; 90-94.
36. Seol H, Lee HJ, Choi Y et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod. Pathol. 2012; 25; 938-948.